IL-2 evaluation, as an adjuvant for an E7 DNA vaccine against HPV-16-related cervical cancer, suggested the potential of this immunoregulatory cytokine in higher infiltration, activation, and degranulation of CD8+ T cells, determined by an increase in IFN-γ and CD107a levels [35, 36]. The gene discussed is CD8A; the disease is cervical carcinoma.